Cargando…
Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033992/ https://www.ncbi.nlm.nih.gov/pubmed/30008693 http://dx.doi.org/10.3389/fneur.2018.00500 |
_version_ | 1783337786939539456 |
---|---|
author | Heinzel, Sebastian Berg, Daniela Binder, Sebastian Ebersbach, Georg Hickstein, Lennart Herbst, Heinz Lorrain, Michael Wellach, Ingmar Maetzler, Walter Petersen, Gudula Schmedt, Niklas Volkmann, Jens Woitalla, Dirk Amelung, Volker |
author_facet | Heinzel, Sebastian Berg, Daniela Binder, Sebastian Ebersbach, Georg Hickstein, Lennart Herbst, Heinz Lorrain, Michael Wellach, Ingmar Maetzler, Walter Petersen, Gudula Schmedt, Niklas Volkmann, Jens Woitalla, Dirk Amelung, Volker |
author_sort | Heinzel, Sebastian |
collection | PubMed |
description | Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases had at least one main hospital discharge diagnosis of PD, or one physician diagnosis confirmed by a subsequent or independent diagnosis or by PD medication in 2015. Prevalence of (co-)occurring diseases, mortality, and healthcare measures in PD cases and matched controls were compared. In 2015, 21,714 prevalent PD cases (standardized prevalence: 511.4/100,000 persons) and 3,541 incident PD cases (standardized incidence: 84.1/100,000 persons) were identified. Prevalence of several (co-)occurring diseases/complications, e.g., dementia (PD/controls: 39/13%), depression (45/22%), bladder dysfunction (46/22%), and diabetes (35/31%), as well as mortality (10.7/5.8%) differed between PD cases and controls. The annual healthcare utilization was increased in PD cases compared to controls, e.g., regarding mean ± SD physician contacts (15.2 ± 7.6/12.2 ± 7.3), hospitalizations (1.3 ± 1.8/0.7 ± 1.4), drug prescriptions (overall: 37.7 ± 24.2/21.7 ± 19.6; anti-PD medication: 7.4 ± 7.4/0.1 ± 0.7), assistive/therapeutic devices (47/30%), and therapeutic remedies (57/16%). The standardized prevalence and incidence of PD in Germany as well as mortality in PD may be substantially higher than reported previously. While frequently diagnosed with co-occurring diseases/complications, such as dementia, depression, bladder dysfunction and diabetes, the degree of healthcare utilization shows large variability between PD patients. These findings encourage a rethinking of the epidemiology and healthcare utilization in PD, at least in Germany. Longitudinal studies of insurance claims data should further investigate the individual and epidemiological progression and healthcare demands in PD. |
format | Online Article Text |
id | pubmed-6033992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60339922018-07-13 Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? Heinzel, Sebastian Berg, Daniela Binder, Sebastian Ebersbach, Georg Hickstein, Lennart Herbst, Heinz Lorrain, Michael Wellach, Ingmar Maetzler, Walter Petersen, Gudula Schmedt, Niklas Volkmann, Jens Woitalla, Dirk Amelung, Volker Front Neurol Neurology Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases had at least one main hospital discharge diagnosis of PD, or one physician diagnosis confirmed by a subsequent or independent diagnosis or by PD medication in 2015. Prevalence of (co-)occurring diseases, mortality, and healthcare measures in PD cases and matched controls were compared. In 2015, 21,714 prevalent PD cases (standardized prevalence: 511.4/100,000 persons) and 3,541 incident PD cases (standardized incidence: 84.1/100,000 persons) were identified. Prevalence of several (co-)occurring diseases/complications, e.g., dementia (PD/controls: 39/13%), depression (45/22%), bladder dysfunction (46/22%), and diabetes (35/31%), as well as mortality (10.7/5.8%) differed between PD cases and controls. The annual healthcare utilization was increased in PD cases compared to controls, e.g., regarding mean ± SD physician contacts (15.2 ± 7.6/12.2 ± 7.3), hospitalizations (1.3 ± 1.8/0.7 ± 1.4), drug prescriptions (overall: 37.7 ± 24.2/21.7 ± 19.6; anti-PD medication: 7.4 ± 7.4/0.1 ± 0.7), assistive/therapeutic devices (47/30%), and therapeutic remedies (57/16%). The standardized prevalence and incidence of PD in Germany as well as mortality in PD may be substantially higher than reported previously. While frequently diagnosed with co-occurring diseases/complications, such as dementia, depression, bladder dysfunction and diabetes, the degree of healthcare utilization shows large variability between PD patients. These findings encourage a rethinking of the epidemiology and healthcare utilization in PD, at least in Germany. Longitudinal studies of insurance claims data should further investigate the individual and epidemiological progression and healthcare demands in PD. Frontiers Media S.A. 2018-06-29 /pmc/articles/PMC6033992/ /pubmed/30008693 http://dx.doi.org/10.3389/fneur.2018.00500 Text en Copyright © 2018 Heinzel, Berg, Binder, Ebersbach, Hickstein, Herbst, Lorrain, Wellach, Maetzler, Petersen, Schmedt, Volkmann, Woitalla and Amelung. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Heinzel, Sebastian Berg, Daniela Binder, Sebastian Ebersbach, Georg Hickstein, Lennart Herbst, Heinz Lorrain, Michael Wellach, Ingmar Maetzler, Walter Petersen, Gudula Schmedt, Niklas Volkmann, Jens Woitalla, Dirk Amelung, Volker Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? |
title | Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? |
title_full | Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? |
title_fullStr | Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? |
title_full_unstemmed | Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? |
title_short | Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? |
title_sort | do we need to rethink the epidemiology and healthcare utilization of parkinson's disease in germany? |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033992/ https://www.ncbi.nlm.nih.gov/pubmed/30008693 http://dx.doi.org/10.3389/fneur.2018.00500 |
work_keys_str_mv | AT heinzelsebastian doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT bergdaniela doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT bindersebastian doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT ebersbachgeorg doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT hicksteinlennart doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT herbstheinz doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT lorrainmichael doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT wellachingmar doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT maetzlerwalter doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT petersengudula doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT schmedtniklas doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT volkmannjens doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT woitalladirk doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany AT amelungvolker doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany |